Share on StockTwits

Stock analysts at Canaccord Genuity raised their price target on shares of Vital Therapies (NYSE:VTL) from $20.00 to $35.00 in a report issued on Friday. Canaccord Genuity’s price objective would suggest a potential upside of 40.62% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Credit Suisse initiated coverage on shares of Vital Therapies in a research note on Friday, July 25th. They set a “buy” rating and a $40.00 price target on the stock. Analysts at William Blair raised their price target on shares of Vital Therapies to $36.00 in a research note on Monday, July 14th.

Shares of Vital Therapies (NYSE:VTL) opened at 24.89 on Friday. Vital Therapies has a 52-week low of $10.66 and a 52-week high of $35.20. The stock’s 50-day moving average is $24.98 and its 200-day moving average is $20.31. The company’s market cap is $525.6 million.

Vital Therapies (NYSE:VTL) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.87. On average, analysts predict that Vital Therapies will post $-3.00 earnings per share for the current fiscal year.

Vital Therapies, Inc is a biotherapeutic company. The Company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure.

Receive News & Ratings for Vital Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.